News & Press

The 2025 Landscape of Digital Headache Technology: A Summary of Dr. Anker Stubberud’s Latest Insights

Multicenter Study on Tension-Type Headache Underway

A major multicenter clinical study investigating biofeedback for tension-type headache has now begun across several Norwegian hospitals. Below, we share key details about the BioTenCer study and our role as technology provider.

Nordic Brain Tech Welcomes a Strong New Board

Nordic Brain Tech has appointed a new Board of Directors to support the company’s next phase of commercialization and international growth. With Cenli now launched and increasing interest from both customers and international stakeholders, the board has been strengthened with experienced leaders across consumer markets, pharma, operations, and scale-up expertise.

Cenli Shipped to Customers in Norway

A major milestone has been reached at Nordic Brain Tech. After years of development, Cenli is now being shipped to hundreds of customers across Norway, marking the official market launch of our first product.

Heading to the European Headache Congress in Lisbon

We’re excited to share that Nordic Brain Tech will be attending the 19th European Headache Congress in Lisbon

Professor and Neurologist Highlights Biofeedback on National TV

Cenli showcased on national TV as an example of how biofeedback can be made accessible at home

NBT Concludes Three Years in the NOME Mentoring Program

Nordic Brain Tech concludes three years as a NOME portfolio company, now becoming an alumni company

Nordic Brain Tech at HLTH Las Vegas 2025

Nordic Brain Tech is heading to HLTH 2025 in Las Vegas as part of the Norwegian delegation hosted by Innovation Norway. We’re joining global leaders in digital health to explore new partnerships, meet investors, and exchange ideas on how biofeedback and digital therapeutics can transform neurological care.

Cenli is launched: biofeedback for stress management

Nordic Brain Tech is proud to share that its daughter company, Cenli AS, has officially launched its first commercial product — the Cenli® biofeedback system for stress management.

Nordic Brain Tech featured in AlbionVC’s European HealthTech Market Map 2025

AlbionVC’s European HealthTech Market Map 2025 highlights the most promising healthtech companies shaping the future of healthcare across Europe

Brain Health for All Ages: Reflections from World Brain Day 2025

World Brain Day 2025 brought global attention to the importance of brain health at every stage of life—a mission we share at Nordic Brain Tech

Why do biofeedback?

Understanding how this powerful technique can help you train your nervous system to feel and function better.

Positive test results bring Cenli biofeedback system closer to launch

Our newly designed sensors have passed key safety and performance tests, supporting our vision for a safer, more connected future in health technology.

Advancing migraine awareness: Nordic Brain Tech joins EAN Public Brain Health Day

In recognition of Migraine Awareness Month this June, Nordic Brain Tech joined a European Academy of Neurology event highlighting the urgent need for better migraine understanding and care. Here’s what we learned—and why awareness matters more than ever.

Exploring the future of healthtech

Last week, we had the pleasure of joining innovators, professionals, and thought leaders at the Healthtech Festival 2025. It was a vibrant gathering filled with inspiring talks, new connections, and meaningful exchanges – all centered around advancing the future of health technology.

Migraine awareness month 2025: shedding light on a common but misunderstood condition

June is Migraine Awareness Month, a time dedicated to raising understanding and compassion for the millions of people living with migraine—a neurological disorder that is far more than just a “bad headache.”

Clinical Trials on Biofeedback Therapy

New data, new momentum, and new hope for people living with headaches. In this article, we share the results from our latest migraine clinical trial, reflect on what they mean for headache care, and introduce the next study already on the horizon.

Press Release: Positive Clinical Trial Results for Cerebri for Migraine Prevention

Oslo, Norway – May 30, 2025 – Nordic Brain Tech, a leader in neurotechnology and digital therapeutics, today announced positive results from a randomized controlled trial evaluating Cerebri, its novel app- and sensor-based therapy for the preventive treatment of migraine.

Brain Twin integrated in electronic health record

Brain Twin is now available for primary care providers in Norway

Nordic Brain Tech featured in expert panel at LSX Nordic Congress

For the first time, the LSX Nordic Congress took place in Norway, gathering innovators, investors, and thought leaders in life sciences and digital health.

The Healthtech Festival 2025

Showcasing the future of digital migraine care at The Healthtech Festival 2025

Introducing Cenli – Making advanced biofeedback accessible

The team behind the upcoming medical product Cerebri is now launching Cenli – a new home-based biofeedback tool that helps users regulate stress and train their nervous system, with no need for medical supervision.

Brain Twin strengthens its market position with new doctor dashboard

Patients can now securely share their headache data with doctors – the first step in our plan to build a powerful clinical platform.

Nordic Brain Tech presenting at Nordic-American Healthcare Conference in New York

Through the Healthcare Innovation Accelerator, Nordic Brain Tech was selected to present in the early stage pitch session among 8 Norwegian companies

Jenny Nesje recognized among Norway's 50 Leading Women in Tech

When Jenny Nesje joined Nordic Brain Tech (NBT), she set out to demonstrate that advanced medical technology for migraine care could be developed and clinically validated in Norway.

Presentation at the 18th European Headache Congress

The BioCer clinical trial has reached a major milestone with the completion of its primary phase.

Nordic Brain Tech selected as 1 of 8 companies in health tech accelerator

The market entry program gives a unique opportunity to meet with investors and prepare for the U.S. market

Nordic Brain Tech and Pfizer Finland has launched Brain Twin in a partnership

With Brain Twin, Finland's first migraine app in Finnish, Pfizer can revolutionize migraine care with cutting-edge technology.

Introducing Calmer: The breathing pacer for migraine relief and stress reduction

Calmer offers a simple yet powerful way to help you relax, de-stress, and soothe your nervous system through guided breathing exercises making you feel.. Calmer!

Brain Twin - Available in The USA

We are beyond excited to bring you the Migraine Diary - Brain Twin, the mobile app designed to revolutionize migraine and headache management. Now officially launched in the United States, Brain Twin empowers users with actionable insights, streamlined tracking, and practical tools – because managing your migraines shouldn’t feel like a guessing game.

Making a diagnosis of migraine

If you are experiencing frequent headaches, and especially if you suspect migraines, talking to your primary care physician is key. They'll delve into your medical history, symptoms, and examine you to make a correct diagnosis.

What is the difference between migraine and other headaches?

When we talk about headaches, we often mean tension headaches, which affect 30% of the population. When we talk about migraines, we mean a characteristic pulsating headache.

Biofeedback

Biofeedback offers a path to understanding and controlling the body's responses, potentially easing migraine symptoms.

Keeping a headache diary

A headache diary is useful for both individuals with headache and their doctors. Based on your symptoms and how often you experience headaches, your doctor determines further treatment.

What is migraine?

Migraine is characterized by recurrent pulsating headaches, often alongside other symptoms such as sensitivity to light, nausea, and vomiting.

284 patients included in the BioCer trial

We've reached a significant milestone by enrolling all 284 patients in our randomized clinical trial, BioCer. With all necessary participants onboard, we are now focused on completing the trial and advancing our research efforts to improve patient outcomes and understand treatment efficacy.